Back to search results

A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)

Abroad (travel likely)RecruitingPHASE2, PHASE3

Conditions

Hepatocellular Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • City of Hope /ID# 261468, Duarte, California, United States

  • City of Hope at Orange County Lennar Foundation Cancer Center /ID# 261669, Irvine, California, United States

  • UC Irvine /ID# 255673, Orange, California, United States

  • The University of Chicago Medical Center /ID# 255674, Chicago, Illinois, United States

  • Alliance for Multispecialty Research LLC Kansas City Oncology /ID# 256830, Merriam, Kansas, United States

  • Norton Cancer Institute /ID# 260775, Louisville, Kentucky, United States

  • Henry Ford Hospital /ID# 255803, Detroit, Michigan, United States

    Study coordinator · (313) 916-8423

  • Metro Minnesota Community Oncology Research Consortium (MMCORC) /ID# 256041, Saint Louis Park, Minnesota, United States

  • Washington University-School of Medicine /ID# 255720, St Louis, Missouri, United States

  • Texas Oncology - Abilene - Antilley Road /ID# 265820, Abilene, Texas, United States

  • Texas Oncology - Dallas - Worth Street /ID# 265806, Dallas, Texas, United States

  • Baylor Scott and White Research Institute /ID# 260853, Dallas, Texas, United States

    Study coordinator · 254-724-1054

  • Oncology and Hematology Associates of Southwest Virginia /ID# 265834, Roanoke, Virginia, United States

  • CHU Grenoble - Hopital Michallon /ID# 256627, La Tronche, Isere, France

  • Institut Gustave Roussy /ID# 258460, Villejuif, Val-de-Marne, France

  • Hôpital Avicenne /ID# 266005, Bobigny, Île-de-France Region, France

  • Hopital Beaujon /ID# 256551, Clichy, Île-de-France Region, France

  • IRCCS Istituto Clinico Humanitas /ID# 256684, Rozzano, Lombardy, Italy

  • IRCCS Ospedale San Raffaele /ID# 256404, Milan, Milano, Italy

  • P.O. Ospedale del Mare /ID# 256410, Naples, Napoli, Italy

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Università Cattolica /ID# 265506, Rome, Roma, Italy

  • IRCCS AOU di Bologna Policlinico Sant Orsola Malpighi /ID# 256412, Bologna, Italy

  • Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone /ID# 256681, Palermo, Italy

  • Fondazione Policlinico Universitario Campus Bio-Medico /ID# 256895, Roma, Italy

  • Puerto Rico Medical Research Center /ID# 262362, Hato Rey, Puerto Rico, Puerto Rico

  • Hospital Universitario Marques de Valdecilla /ID# 255769, Santander, Cantabria, Spain

  • Hospital Universitario Reina Sofia /ID# 255779, Córdoba, Cordoba, Spain

  • Hospital Universitario Puerta de Hierro - Majadahonda /ID# 255778, Majadahonda, Madrid, Spain

  • Hospital Universitario Vall d'Hebron /ID# 255771, Barcelona, Spain

  • Hospital General Universitario Gregorio Maranon /ID# 255772, Madrid, Spain

  • Hospital Universitario Virgen del Rocio /ID# 255776, Seville, Spain

  • Hospital Universitario Miguel Servet /ID# 255774, Zaragoza, Spain

    Study coordinator · 976 76 55 00

  • National Taiwan University Hospital /ID# 256168, Taipei City, Taipei, Taiwan

  • China Medical University Hospital /ID# 256764, Taichung, Taiwan

  • Taichung Veterans General Hospital /ID# 259405, Taichung, Taiwan

  • National Cheng Kung University Hospital /ID# 256766, Tainan, Taiwan

  • Taipei Veterans General Hosp /ID# 256169, Taipei, Taiwan

Study leads

  • ABBVIE INC.

    Study Director

    AbbVie

View source on ClinicalTrials.gov(opens in a new tab)